LBX1 Inhibitors
Chemical inhibitors of LBX1 can exert their inhibitory effects through various cellular signaling pathways that are crucial for the protein's role in differentiation and cellular processes. PD 0332991, a CDK4/6 inhibitor, arrests the cell cycle, which can reduce the functional necessity for LBX1 in processes that are regulated by cell cycle progression. Similarly, the PI3K pathway, important for differentiation signals, can be targeted by chemicals like LY294002 and Wortmannin. Their inhibitory action on PI3K attenuates the downstream signals that LBX1 relies on for promoting differentiation. The MAPK/ERK and p38 MAP kinase pathways are also central to differentiation and stress responses, and their interruption by U0126 and SB203580, respectively, disrupts the signaling cascades that could facilitate LBX1's activity in the cell.
Further, the JNK pathway, another branch of the MAPK family, is implicated in signaling for cellular differentiation and is sensitive to inhibition by SP600125, which could lead to a decrease in LBX1 activity. PD98059 targets the MEK/ERK pathway, preventing the activation of ERK and consequently disrupting LBX1's involvement in differentiation signaling. Dorsomorphin's inhibition of BMP signaling impedes the bone morphogenetic proteins' (BMPs) role in development and differentiation, which can reduce the activity of LBX1 associated with these processes. PKC, which is involved in a multitude of cellular processes including differentiation, can be inhibited by Go 6983, thereby attenuating the signaling that LBX1 may utilize, reducing its activity. Lastly, mTOR inhibitors such as Rapamycin and AZD8055 can suppress LBX1's function by targeting the mTOR pathway, which is involved in cell growth and proliferation, processes where LBX1 is known to play a role. The inhibition of mTOR results in diminished signaling for growth and proliferation, thus affecting the functional involvement of LBX1 in these pathways.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that impairs cell cycle progression. LBX1 has been implicated in the regulation of cell differentiation and proliferation. Palbociclib, by inhibiting CDK4/6, may halt the cell cycle, potentially reducing the activity of LBX1 as it is less required for cell differentiation processes that are under cell cycle control. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K signaling is important for many cellular functions including differentiation. Since LBX1 is involved in muscle differentiation, inhibition of the PI3K pathway by LY294002 can lead to reduced activity of LBX1 by limiting the signaling pathways necessary for its role in differentiation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key enzymes in the MAPK/ERK pathway. LBX1 is associated with tissue-specific differentiation, and the MAPK/ERK pathway is crucial for transmitting signals that lead to differentiation. Inhibition by U0126 would disrupt this signaling, therefore inhibiting the functional activity of LBX1 in the differentiation pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is involved in stress responses and differentiation. The p38 MAP kinase pathway is one potential signaling cascade that LBX1 may function within, to mediate cellular differentiation. Inhibition by SB203580 can suppress LBX1 activity indirectly by blocking the downstream signaling required for its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that would similarly inhibit the PI3K pathway, as LY294002 does. By inhibiting PI3K, Wortmannin could reduce LBX1 activity by curtailing the signaling that promotes the cellular differentiation processes in which LBX1 is involved. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. mTOR signaling is involved in cell growth and proliferation, processes in which LBX1 has a role. By inhibiting mTOR, Rapamycin can indirectly inhibit LBX1 function by reducing the cellular demand for differentiation and proliferation signals where LBX1 might be active. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathways. It would inhibit JNK's role in signaling for cellular processes such as differentiation and apoptosis. Through this inhibition, LBX1's role in differentiation may be indirectly suppressed as the JNK pathway is a possible signaling route for LBX1 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific MEK inhibitor that prevents the activation of ERK, which is part of the MAPK pathway. By inhibiting this pathway, PD98059 would disrupt downstream signaling necessary for LBX1 to promote cellular differentiation, thereby inhibiting the protein's functional activity. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin is an inhibitor of BMP signaling by inhibiting BMP type I receptors. LBX1 is involved in developmental processes regulated by BMP signaling. Inhibition of BMP signaling by Dorsomorphin could lead to decreased LBX1 activity as its role in promoting differentiation is suppressed. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go 6983 is a pan-protein kinase C (PKC) inhibitor. PKC is involved in a multitude of cellular processes including differentiation. LBX1, having a role in cellular differentiation, may rely on PKC-mediated signaling for its activity. Therefore, Go 6983 can inhibit LBX1 function by attenuating the PKC signaling that LBX1 may utilize. | ||||||